Summit Therapeutics Inc.
SMMT
주식 순위
#1666
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
주가
$16.14
마지막 동기화: 2026-10-20
시가총액
$12.87B
변동 (1일)
3.65%
변동 (1년)
-13.88%
국가
US
거래 Summit Therapeutics Inc. (SMMT)
카테고리
Healthcare
Summit Therapeutics Inc. (SMMT)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 18.69
Summit Therapeutics Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 18.69입니다. 2023년 말 기준 P/B 비율은 20.82였습니다.
Summit Therapeutics Inc.의 P/B 비율 기록 (2004 ~ 2026)
매년 말 P/B 비율
| 연도 | P/B 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 18.69 | -43.35% |
| 2024 | 32.99 | 58.49% |
| 2023 | 20.82 | 220.87% |
| 2022 | 6.49 | 117.76% |
| 2021 | 2.98 | -27.56% |
| 2020 | 4.11 | 536.54% |
| 2019 | 0.65 | -98.56% |
| 2018 | 45.00 | -138.35% |
| 2017 | -117.33 | -1,034.33% |
| 2016 | 12.56 | 5.70% |
| 2015 | 11.88 | -48.78% |
| 2014 | 23.20 | 2.85% |
| 2013 | 22.55 | 13.41% |
| 2012 | 19.89 | -52.35% |
| 2011 | 41.73 | 29.00% |
| 2010 | 32.35 | 6.43% |
| 2009 | 30.39 | 569.58% |
| 2008 | 4.54 | -3.53% |
| 2007 | 4.71 | -38.65% |
| 2006 | 7.67 | 60.25% |
| 2005 | 4.79 | -99.36% |
| 2004 | 747.02 | 0.00% |
유사 기업 또는 경쟁사의 P/B 비율
| 회사 | P/B 비율 | P/B 비율 차이 | 국가 |
|---|---|---|---|
| 6.251 | -66.55% |
US
|
|
| 13.2547 | -29.08% |
US
|
|
| 4.208 | -77.48% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -66.92% |
NL
|
